Pfizer, Inc.(PFE) - Stock detail

Pfizer, Inc.

US
PFE
Pfizer Inc.(Listing date: 01/17/1944)

Pfizer Inc. was incorporated under the laws of Delaware on June 2, 1942. It is a research-based global biopharmaceutical company. Using science and global resources, the company brings therapies that extend and significantly improve people's lives through the discovery, development, manufacturing and distribution of healthcare products, including innovative medicines and vaccines. The company operates in both developed and emerging markets, committed to advancing health, prevention, treatment and cure for the world's most feared diseases of our time. It collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare services worldwide.

AI Rating

Rating methodology
Latest close (chg%)27.56+1.25%
Buy price
27.56
Target price27.50
Sell price27.00
P/E TTM19.48
P/E18.50
Confidence70%
Risk score50/100
AI Summary
Stock is in a defined trading range ($27.00-$28.50) ahead of binary Q1 earnings event. Hold with clear post-earnings triggers: buy above $28.50, sell below $27.00. Respects technical consolidation, dividend support (~6% yield), and event risk without speculative positioning.

Alpha Score

0-10
  • Trend（Score 4/10）

    Pfizer (PFE) is at a technical inflection point, consolidating after a rally, with a mixed technical picture that leans cautiously positive in the very short term but lacks strong directional momentum.

  • Valuation（Score 5/10）

    Valuation metrics suggest the stock is trading close to fair value. The P/E of 19.48x (TTM) and P/B of 1.75x are reasonable for a large-cap pharmaceutical company. The current price falls within the calculated fundamental valuation range of $21.76 to $29.92.

  • Financial strength（Score 5/10）
    Financial health shows a mixed picture. The company has sufficient liquidity but with a thin margin of safety. Leverage is at a moderate and manageable level for the industry.
  • Profitability（Score 4/10）
    Profitability has been under pressure with declining revenue and net income. Gross margins remain robust, but net margins are impacted by high operating expenses. Return on equity and assets are modest.
  • Sentiment（Score 4/10）
    Pfizer presents a mixed but cautiously optimistic picture with strong dividend appeal and long-term pipeline strategy offset by near-term revenue headwinds, leading to a neutral 'Hold' recommendation ahead of Q1 earnings.
Latest price
$27.56+1.25%
Market cap156.77B
P/E TTM19.48
P/E18.50
Volume30.02M
Turnover824.93M